The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion
作者: Christoph BurdelskiDevi MenanMaria Christina TsourlakisMartina KluthClaudia Hube-MaggNathaniel MellingSarah MinnerChristina KoopMarkus GraefenHans HeinzerCorinna WittmerGuido SauterRonald SimonThorsten SchlommStefan SteurerTill Krech
作者单位: 1University Medical Center Hamburg-Eppendorf
2Institute of Pathology, University Medical Center Hamburg-Eppendorf
3University Medical Center Hamburg- Eppendorf
刊名: BMC Cancer, 2015, Vol.15 (1)
来源数据库: Springer Journal
DOI: 10.1186/s12885-015-1555-8
关键词: Prostate cancerERG fusionPTEN deletionSENP1SUMOImmunohistochemistryTissue microarray
英文摘要: Abstract(#br) Background(#br)Posttranscriptional protein modification by SUMOylation plays an important role in tumor development and progression. In the current study we analyzed prevalence and prognostic impact of the de-SUMOylation enzyme SENP1 in prostate cancer.(#br) Methods(#br)SENP1 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancer specimens. Results were compared to tumor phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN , and biochemical recurrence.(#br) Results(#br)SENP1 immunostaining was detectable in 34.5 % of 9,516 interpretable cancers and considered strong in 7.3 %, moderate in 14.9 % and weak in 12.3 % of cases. Strong SENP1 expression was linked to advanced pT stage (p < 0.0001), high Gleason...
全文获取路径: PDF下载  Springer  (合作)
影响因子:3.333 (2012)

  • peptidase 肽酶
  • lacking 缺少的
  • ERG 视网膜电图
  • prostate 前列腺
  • prognostic 预测的
  • deletion 缺失
  • cancer 癌症
  • specific 
  • positive 阳片
  • fusion 融解